急性缺血性卒中血管内治疗前静脉阿替普酶的随机试验
该开放标签、多中心、随机试验在欧洲纳入可直接提供EVT且符合静脉阿替普酶和EVT条件的卒中患者,1:1随机接受单纯EVT或静脉阿替普酶后EVT(标准治疗)。主要终点为90天改良Rankin量表功能结局,评估单纯EVT相比阿替普酶后EVT的优效性和非劣效性(OR的95%CI下限非劣效界值0.8)。共分析539例患者,90天mRS中位数单纯EVT组为3(IQR 2-5),阿替普酶后EVT组为2(IQR 2-5),校正共同OR 0.84(95%CI 0.62-1.15;P=0.28),既未显示优效也未显示非劣效。死亡和症状性颅内出血两组相似。
要点
- 欧洲多中心随机试验纳入539例符合静脉阿替普酶和EVT条件的卒中患者,比较单纯EVT与阿替普酶后EVT。
- 90天mRS中位数单纯EVT组为3(IQR 2-5),阿替普酶后EVT组为2(IQR 2-5),校正共同OR 0.84(95%CI 0.62-1.15;P=0.28)。
- 单纯EVT既未显示优于也未显示非劣于阿替普酶后EVT(非劣效界值OR 95%CI下限0.8)。
- 死亡率单纯EVT组20.5% vs 阿替普酶后EVT组15.8%(校正OR 1.39;95%CI 0.84-2.30)。
- 症状性颅内出血单纯EVT组5.9% vs 阿替普酶后EVT组5.3%(校正OR 1.30;95%CI 0.60-2.81)。
适用人群与场景
- 欧洲卒中患者,直接到能提供EVT的医院就诊,且符合静脉阿替普酶和EVT条件。
诊断标准与关键阈值
- 主要终点为90天改良Rankin量表评分(范围0[无残疾]至6[死亡])。
- 非劣效性界值为两组OR的95%CI下限0.8。
处置流程与药物剂量
- 患者1:1随机接受单纯EVT或静脉阿替普酶后EVT(标准治疗)。
研究设计与关键结果
- 开放标签、多中心、随机试验,纳入539例患者,比较单纯EVT与静脉阿替普酶后EVT。
- 90天mRS中位数:单纯EVT组3(IQR 2-5) vs 阿替普酶后EVT组2(IQR 2-5);校正共同OR 0.84(95%CI 0.62-1.15;P=0.28),既未显示优效也未显示非劣效。
- 死亡率:单纯EVT组20.5% vs 阿替普酶后EVT组15.8%(校正OR 1.39;95%CI 0.84-2.30)。
- 症状性颅内出血:单纯EVT组5.9% vs 阿替普酶后EVT组5.3%(校正OR 1.30;95%CI 0.60-2.81)。
证据类型、等级与局限
- 证据类型:开放标签、多中心、随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在欧洲患者中,单纯EVT在90天残疾结局方面既不优于也不非劣于静脉阿替普酶后EVT;症状性颅内出血发生率两组相似。
指南或共识出处
- MR CLEAN-NO IV试验(ISRCTN80619088),由Collaboration for New Treatments of Acute Stroke consortium等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations.
METHODS: We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive EVT alone or intravenous alteplase followed by EVT (the standard of care). The primary end point was functional outcome on the modified Rankin scale (range, 0 [no disability] to 6 [death]) at 90 days. We assessed the superiority of EVT alone over alteplase plus EVT, as well as noninferiority by a margin of 0.8 for the lower boundary of the 95% confidence interval for the odds ratio of the two trial groups. Death from any cause and symptomatic intracerebral hemorrhage were the main safety end points.
RESULTS: The analysis included 539 patients. The median score on the modified Rankin scale at 90 days was 3 (interquartile range, 2 to 5) with EVT alone and 2 (interquartile range, 2 to 5) with alteplase plus EVT. The adjusted common odds ratio was 0.84 (95% confidence interval [CI], 0.62 to 1.15; P = 0.28), which showed neither superiority nor noninferiority of EVT alone. Mortality was 20.5% with EVT alone and 15.8% with alteplase plus EVT (adjusted odds ratio, 1.39; 95% CI, 0.84 to 2.30). Symptomatic intracerebral hemorrhage occurred in 5.9% and 5.3% of the patients in the respective groups (adjusted odds ratio, 1.30; 95% CI, 0.60 to 2.81).
CONCLUSIONS: In a randomized trial involving European patients, EVT alone was neither superior nor noninferior to intravenous alteplase followed by EVT with regard to disability outcome at 90 days after stroke. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by the Collaboration for New Treatments of Acute Stroke consortium and others; MR CLEAN-NO IV ISRCTN number, ISRCTN80619088.).
参考来源
- LeCouffe NE, Kappelhof M, Treurniet KM, et al. A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. N Engl J Med. 2021. PMID: 34758251. doi:10.1056/NEJMoa2107727
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。